transformation (r=-0-81, p<0 0001). A significant correlation was also found between serum creatine kinase activity and serum phosphate concentration in the two patients (cases 1 and 2) (r= 0-95 and 0 97, respectively). All patients who had hyperphosphataemia but normal serum calcium concentrations, however, had normal creatine kinase activities (cases 12-19).
Comment
Hypocalcaemia without any clinically obvious cardiac or skeletal muscle disorder can increase serum creatine kinase activity appreciably. Considerable individual variation in the activity of serum creatine kinase is seen in hypocalcaemic patients. High creatine kinase activity is more likely in cases of severe hypocalcaemia.
Occasional reports have noted raised serum creatine kinase activity in patients with hypocalcaemia due to hypoparathyroidism.'-5 Serum creatine kinase activity may also be associated with the hypocalcaemia of chronic renal failure (table). In cases in which successful correction of serum calcium concentration occurred (cases 1 and 2) serum creatine kinase activity also became normal.
The mechanism by which hypocalcaemia increases serum creatine kinase activity is not known. Apart from one patient (case 1) none had any clinically obvious disorder of the muscle, such as spasm or fasciculation.
It is calcium, not phosphate, concentration that affects serum creatine kinase activity, but we cannot explain the variation in serum creatine kinase activity in patients with similar serum calcium concentrations. Factors other than serum calcium concentration may be important, and so far we have been unable to establish whether the duration of hypocalcaemia is relevant. Whatever the mechanism, it does not appear to be a non-specific "sick cell" phenomenon.
When high serum creatine kinase activity is noted hypocalcaemia should be excluded. 
Cases notified to Netherlands centre
The table summarises the five cases notified to the Netherlands Centre for Monitoring of Adverse Reactions to Drugs. All the patients had taken paracetamol for minor complaints-for example, headache and myalgia. The outcome of the acute hypersensitivity reactions was favourable in all cases, although one patient (case 2) had needed clemastine. This patient (with a history of hay fever and allergy to house dust) had used paracetamol one year previously without adverse effects. He also took aspirin occasionally without ill effects. The third patient had previously used phenylbutazone and oxyphenbutazone but had never experienced adverse reactions to these drugs. Although some patients had used other drugs concurrently, these were either continued or not temporally related to the acute reaction. None of the patients were reported to have experienced symptoms of hypersensitivity to products containing caffeine such as coffee or soft drinks.
Cases notified to WHO centre
In addition to the above cases, by 1 July 1984 the WHO Collaborating Centre for International Drug Monitoring (Uppsala, Sweden) had received 50 reports of acute hypersensitivity reactions developing the same day that tablets of paracetamol were taken; in reports where the time interval was explicitly recorded the symptoms usually appeared within one hour after taking the drug. Forty four of these reports came from doctors or hospitals and concerned 27 female patients (mean age 37 (range 3-79) years) and 16 male patients (mean age 30 (1-66) years). In one case age and sex were not given. The remaining six reports mainly arrived indirectly-for example, through the drug industry-and are excluded from analysis.
Four of the 44 cases were reported as anaphylactic shock (two cases), anaphylactic reaction (one), or allergic reaction (one) without a detailed description of the symptoms. In the remaining 40 cases the reported symptoms were as follows (number of reports in parentheses; some patients had more than one symptom): Skin-erythematous or maculopapular rashes (12), urticaria (18), flushing (1), angioedema (8); respiratory systemdyspnoea or bronchospasm (16); circulatory system-hypotension, circulatory failure, or collapse (4), chest pain (3); miscellaneous (10)-often secondary to other symptoms (for example, pruritus, palpitations).
In 21 cases a skin reaction was the only reported manifestation, whereas in four there were only respiratory symptoms. In 15 cases more than one system was affected. In seven patients the symptoms recurred when the drug was readministered. As is often the case with spontaneous reports, little was known about the prior history of allergy in these patients. One patient from the United Kingdom had experienced an analogous reaction to aspirin, whereas two Swedish patients had a history of hypersensitivity reactions to penicillin, sulphonamides, and nitrofurantoin (one case) and to non-steroidal anti-inflammatory drugs and tartrazine (one). Most reports concerned paracetamol as a single ingredient or combined with caffeine. Unfortunately, in several reports the brand names were not stated.
Comment
The five cases reported to the Netherlands Centre for Monitoring of Adverse Reactions to Drugs showed that the ingestion of paracetamol may sometimes be followed by acute hypersensitivity reactions. This is supported by the reports collected internationally by the WHO centre. The clear temporal relation in all cases and the positive reaction to rechallenge in eight provide evidence for a causal relation. We regard caffeine as an unlikely cause and can find no published report of hypersensitivity reactions to caffeine; moreover, several patients used preparations containing paracetamol as the only active ingredient. Alternatively, an excipient may have been responsible, at least in some patients. Unfortunately, however, brand names were not always mentioned, but in many countries the identity of excipients is not disclosed. Hence the possible role of excipients is difficult to assess. In this respect at least two reports (one from Britain, one from the Netherlands) referred to products that contain only paracetamol and no preservative or flavouring or colouring agent (paracetamol BP and paracetamol FNA respectively).
The mechanism of these reactions is not clear. We know that analgesics with strong anti-inflammatory properties may cause anaphylactoid reactions, probably by non-immunological release of vasoactive In view of the worldwide use of paracetamol and the paucity of reports of hypersensitivity reactions the incidence of these reactions to paracetamol is presumably low. Nevertheless, since anaphylactic reactions are serious and may be fatal medical practitioners should be aware of their possible occurrence after the ingestion of tablets containing paracetamol.
We thank the National Drug Monitoring Centres of Australia (Dr J McEwen), Canada (Dr E Napke), Finland (Dr E Alhava), Israel (Professor H Halkin), New Zealand (Professor I R Edwards), Norway (Dr L Kjeldaas), Spain (Professor J R Laporte), Sweden (Dr B E Wiholm), the United Kingdom (Dr J C P Weber), and the United States (Dr J K Jones) for permission to use their data. 
Photosensitivity during treatment with azapropazone
Azapropazone is a non-steroidal anti-inflammatory drug and was first launched in 1970. We have found only one published case report of photosensitivity during treatment with azapropazone.1 Neither
Martindale: The Extra Pharmacopoeia nor the Side Effects of Drugs series mentions this adverse reaction. The product information for azapropazone in some countries now mentions photosensitivity as an occasional adverse effect.2 3 The experience of the World Health Organisation's programme for monitoring adverse reactions indicates, however, that reports of photosensitivity as a proportion of reports of all reactions is higher for azapropazone than for almost all other nonsteroidal anti-inflammatory drugs.
Methods and results
This study was based on 190 reports of photosensitivity thought to be associated with azapropazone. The reports were submitted by doctors to their national drug monitoring centres in Belgium, Denmark, Ireland, the Netherlands, Sweden, and the United Kingdom and forwarded to the WHO Collaborating Centre for International Drug Monitoring before September 1984. Eighteen reports already mentioned in publications from two of the national drug monitoring centres were included in the study.4 5 Yearly number of reports of adverse reactions in which azapropazone eas the drug implicated and proportion of these adverse reactions that were photosensitivity 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 Total The possibility of a causal relation between azapropazone and photosensitivity was assessed at the national centres for 154 reports. A causal relation was considered to be certain in six, probable in 138, and possible in 10. Of the patients affected, 117 were women, 72 were men, and in one case sex was not stated. Ninety seven patients were aged 60 or more. Information on age was lacking in 17 reports.
The table shows the number of cases of photosensitivity by year. The greatest number of reactions occurred in April (43 cases) followed by May (42), March (24), and June (18). The doses given to patients who developed photosensitivity were generally within the recommended range of 600-1200 mg daily, although 40% of the reports analysed lacked information about dosage. In 116 reports no drug other than azapropazone was mentioned.
Twenty seven patients experienced the reaction within the first week of treatment, 104 after one to five weeks of treatment, and 36 patients after more than five weeks' treatment.
In most reports the adverse effect was described only as a photosensitivity reaction, reversible by withdrawal of treatment. A few reports included more detailed descriptions of the reactions such as oedema, eczematous eruptions, maculopapular rashes, or dermatitis. In general the photosensitivity did not seem to affect the patients seriously.
Comment
The scarcity of published reports of photosensitivity induced by azapropazone suggests that this phenomenon is rare. Systems for spontaneous reporting of adverse reactions are not well suited for estimations of incidence, particularly when, as in this case, no estimate of drug consumption is available. The main factor indicating that photosensitivity is a fairly frequent reaction to azapropazone was the number of reported cases as a proportion of the total number of suspected reactions. This fraction was higher for azapropazone than for any other non-steroidal anti-inflammatory drug except benoxaprofen, according to reports of adverse reactions from the six countries that contributed to this survey. The table shows that this proportion rose from around 10% in 1976-9 to more than 20% in 1980 and subsequent years. This may reflect a heightened awareness among doctors of photosensitivity reactions related to drugs, created by the publicity given to benoxaprofen.
The finding that April and May were the months in which reactions most commonly occurred contrasts with results of a corresponding study based on all reports of photosensitivity, irrespective of the incriminated drug, submitted to the WHO from countries in the northern hemisphere, which shows a symmetric distribution around June and July.
In view of our data we recommend that prescribing doctors advise patients taking azapropazone to limit their exposure to direct sunlight.
We thank all the doctors who reported the reactions, the national drug monitoring centres for supplying the data, and all those who provided useful comments on criticism of the analysis-namely, Mr B Huyghe, Belgium; Ms I Kovacs, Denmark; Dr A Scott, Ireland; Dr K van Dijke, the Netherlands; Dr B-E Wiholm, Sweden; and Dr P Weber, United Kingdom. This article expresses the views of the authors and does not necessarily represent those of the World Health Organisation.
